Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment.
Saved in:
| Title: | Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. |
|---|---|
| Authors: | Cabrera-Rode E; Department of Immunology of Diabetes Mellitus, National Institute of Endocrinology, Vedado, Havana, Cuba. diabetes@infomed.sld.cu, Perich P, Diaz-Horta O, Tiberti C, Molina G, Arranz C, Martin JM, Licea M, De Leiva AD, Puig-Domingo M, Dimario U |
| Source: | Autoimmunity [Autoimmunity] 2002 Nov; Vol. 35 (7), pp. 469-74. |
| Publication Type: | Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 8900070 Publication Model: Print Cited Medium: Print ISSN: 0891-6934 (Print) Linking ISSN: 08916934 NLM ISO Abbreviation: Autoimmunity Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
